H., Medical Director 50 million Americans have GHI (genital herpes infections).This ranks GHI as being one of the most prevalent medical conditions in the country.The results of almost all of this information, when looking at the literature honestly, is that the vaccines may offer a very slight benefit for preventing transmission and treating infection. Specifically, Mastrolorenzo’s previous work in Florence used multiple injections of vaccine over many weeks to produce a modest reduction in outbreak frequency among infected women. Vaccine developed in England gave initially high marks for reducing recurrences and preventing transmission.American study of the same vaccine did not reveal the same findings.Further reading will add greater depth to your reference information, but you need only read a few paragraphs to get the gist.Vaccines for GHI have been being produced for at least twenty years, especially in Europe.Whether or not this can even be accomplished is uncertain at this time and represents one of the forefronts of research into GHI vaccines.
However: No study has convincingly shown complete protection from infection after a vaccine nor the complete elimination of outbreaks.Both vaccines are available for those interested, but one might have to travel to that country to take it.The Bottom Line: There MAY be some benefit from these vaccines to reducing recurrence frequency.They do NOT eradicate the virus from the body, however, and do not prevent recurrences.Numerous articles have suggested that these European vaccines also reduce transmission of GHI to non-infected partners. Read this carefully, though, before you consider booking a flight: It is difficult to separate out from the effect of the vaccine the other effect of “patient counseling”, that is, being “smart” about managing GHI.